ERNA vs MA · P/E 0.0, rev $582.0K vs P/E 38, rev $32.79B
Eterna Therapeutics Inc (ERNA) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
ERNA currently screens at market cap $6.9M and trailing P/E 0.0. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the ERNA and MA stock pages for the full models.
Not investment advice.